复发性恶性晶状体:持续保守治疗咪喹莫特还是重复手术?长期随访皮肤镜病例研究。

Q3 Medicine

Experimental oncology Pub Date : 2023-06-26 DOI:10.15407/exp-oncology.2023.01.125

V De Giorgi, B Zuccaro, F Silvestri, F Venturi, J Colombo, L Trane

{"title":"复发性恶性晶状体:持续保守治疗咪喹莫特还是重复手术?长期随访皮肤镜病例研究。","authors":"V De Giorgi, B Zuccaro, F Silvestri, F Venturi, J Colombo, L Trane","doi":"10.15407/exp-oncology.2023.01.125","DOIUrl":null,"url":null,"abstract":"A case of recurrent lentigo maligna in a 45-year-old woman is presented. The disease relapsed several times following the surgical excision of the lesion. An alternative treatment with imiquimod 5% cream was then used. After 4 years of follow-upfrom the last surgery, this treatment achieved total clearance of the lesion. The problems of lentigo maligna diagnosis and treatment are discussed.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"45 1","pages":"125-129"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY.\",\"authors\":\"V De Giorgi, B Zuccaro, F Silvestri, F Venturi, J Colombo, L Trane\",\"doi\":\"10.15407/exp-oncology.2023.01.125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A case of recurrent lentigo maligna in a 45-year-old woman is presented. The disease relapsed several times following the surgical excision of the lesion. An alternative treatment with imiquimod 5% cream was then used. After 4 years of follow-upfrom the last surgery, this treatment achieved total clearance of the lesion. The problems of lentigo maligna diagnosis and treatment are discussed.\",\"PeriodicalId\":12287,\"journal\":{\"name\":\"Experimental oncology\",\"volume\":\"45 1\",\"pages\":\"125-129\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15407/exp-oncology.2023.01.125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2023.01.125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

一例复发的恶性黄斑在一个45岁的妇女提出。手术切除病变后，疾病复发了几次。然后使用5%咪喹莫特乳膏进行替代治疗。从最后一次手术开始，经过4年的随访，这种治疗实现了病灶的完全清除。讨论了恶性黄斑的诊断和治疗问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY.

A case of recurrent lentigo maligna in a 45-year-old woman is presented. The disease relapsed several times following the surgical excision of the lesion. An alternative treatment with imiquimod 5% cream was then used. After 4 years of follow-upfrom the last surgery, this treatment achieved total clearance of the lesion. The problems of lentigo maligna diagnosis and treatment are discussed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.